Industry-leading oncologists to discuss the use of molecular profiling in individualising cancer care
VIENNA, AUSTRIA, Sept. 27, 2012 – Caris Life Sciences, a leading biosciences company focused on enabling personalised healthcare through molecular profiling and blood-based diagnostic services, will host a satellite symposium at the 2012 annual meeting of the European Society for Medical Oncology (ESMO) in Vienna, Austria. The Symposium will feature presentations by a number of distinguished personalised medicine experts, with specific discussion about how personalised medicine is practised in leading cancer centers in both Europe and the United States, as well as how utilising personalised medicine applications like molecular profiling can help guide individualised therapeutic planning for cancer patients.
The panel of expert presenters includes Jose Baselga, M.D., Chief of the Division of Hematology/Oncology and Associate Director at Massachusetts General Hospital Cancer Center in Boston, Mass., where he also serves as a Professor of Medicine at Harvard Medical School. Fabrice André, M.D., Ph.D., medical oncologist and current Director of INSERM Unit U981, a laboratory dedicated to personalized medicine development, will also present, along with Ramesh K. Ramanathan, M.D., Medical Director of the Virginia G. Piper Cancer Center (VGPCC) Clinical Trials Program at Scottsdale Healthcare, and Professor Robert Leonard, medical oncologist, Professor of Cancer Studies at Imperial College London.
“We as oncologists must now shift our focus to improving outcomes for individual patients by capitalising on emerging personalised medicine technologies like molecular profiling,” says Symposium Chair Person Dr. Peter Harper, founding partner of the London Oncology Clinic and noted cancer treatment researcher. “This Satellite Symposium provides an opportunity to hear how leading cancer experts are bringing the latest information from the field of personalised medicine into everyday clinical practice.”
The Satellite Symposium will be held Friday, 28th September 2012, 14:30 – 16:30 p.m., at Austria Center Vienna, Hall H.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic, and theranostic services. The company’s evidence-based molecular profiling service, Caris Target Now™, matches molecular data generated from a patient’s tumor with biomarker/drug associations derived from the world’s leading clinical cancer literature. Caris Target Now uses the most advanced and clinically relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company’s proprietary Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like Caris Target Now and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.eu or www.caristargetnow.com.
###
Media Inquiries:
Just Health PR
Helen Laurence
Direct dial: +44 20 8877 8401
Helen@JustHealthPR.com